银发经济或成下一个风口(共8份)
银发经济或成下一个风口
-
艾媒咨询|2024-2025年中国运动鞋服市场运行状况及消费需求数据监测报告
近年来,中国运动鞋服市场保持持续增长态势。全球新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询)最新发布的《2024-2025年中国运动鞋服市场运行状况及消费需求数据监测报告》显示,2023年中国运动鞋服市场规模已跃升至4926亿元。这一显著增长背后,国潮元素的兴起扮演了重要角色。随着消费者对本土文化的认同感逐渐增强,国潮风格在运动鞋服设计中的应用越来越广泛,深受市场欢迎。这既满足了消费者对个性化追求的需求,也为品牌带来了差异化竞争的新机会,进一步丰富了产品的文化内涵,提升了本土品牌在国际市场上的影响力。展望未来,国潮元素的深度融合与创新将成为推动中国运动鞋服市场持续上升的关键因素。预计到2025年,中国运动鞋服市场规模有望攀升至5989亿元,预示着”国潮热潮”下国货品牌的崛起以及市场的巨大潜力。
In recent years, China's sports shoes and clothing market has maintained a continuous growth trend. According to the latest "2024-2025 China sneaker-wear Market Operation and Consumer Demand Data Monitoring Report" released by iiMedia Research, a third-party data mining and analysis institution in the global new economy industry, the market size of China's sneaker-wear has jumped to 492.6 billion yuan in 2023. Behind this significant growth, the rise of the national tide element plays an important role. With the gradual enhancement of consumers' sense of identity of local culture, the national tide style is more and more widely used in the design of sports shoes and clothing, and is welcomed by the market. This not only meets the needs of consumers for personalized pursuit, but also brings new opportunities for differentiated competition for brands, further enrichis the cultural connotation of products, and enhances the influence of local brands in the international market. Looking to the future, the deep integration and innovation of national tide elements will become a key factor to promote the continued rise of China's sports shoes and clothing market. It is expected that by 2025, the market size of China's sports shoes and clothing is expected to climb to 598.9 billion yuan, indicating the rise of domestic brands under the "national tide boom" and the huge potential of the market. -
艾媒咨询|2024-2025年中国头皮疗养行业发展趋势分析报告
随着现代生活节奏加快、压力增大,头皮问题逐渐增多,消费者对于头皮疗养产品的需求日益增长。全球新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询)最新发布的《2024-2025年中国头皮疗养行业发展趋势分析报告》数据显示,2023年中国护发产品市场规模达到620.90亿元,同比增长3.4%,预计2025年将达691.07亿元。随着居民对头皮健康问题的日益重视,头皮疗养行业有望得到新的发展。
With the acceleration of the pace of modern life and the increase of pressure, scalp problems are gradually increasing, and the demand of consumers for scalp therapy products is growing. According to the latest "Analysis report on the development trend of China's scalp therapy industry from 2024 to 2025" released by iiMedia Research, a third-party data mining and analysis institution in the global new economy industry, the market size of China's hair care products will reach 62.09 billion yuan in 2023, an increase of 3.4%. It is expected to reach 69.11 billion yuan by 2025. With the increasing attention of residents to scalp health problems, scalp therapy industry is expected to get new development. -
艾媒咨询|2020年第三季度中国中药材行业数据监测季度报告
本报告研究涉及企业/品牌/案例:同仁堂、香雪制药、白云山。
数据显示,2020年第三季度,中药材价格指数迎来上涨周期。艾媒咨询分析师认为,受动物类等少数品种拉动影响,预计2020年10-11月中药材指数会持续走高,但是在12月维稳。据调查,绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营,采取减少压货炒作等经营方式。因而,预计中药材市场在2020年末旺季会有一波行情的走高,但随着旺季结束,明年年初的价格会重新回落,随着疫情的常态化,中药材市场行情预期会呈周期性波动的态势。
Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation. -
艾媒咨询|2021年中国运动鞋服行业发展现状与市场调研分析报告
本报告研究涉及企业/品牌/案例:华利股份,申洲国际,安踏,李宁,特步,361°,阿迪达斯,迪卡侬
2021年5月7日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research (艾媒咨询) 发布《2021年中国运动鞋服行业发展现状与市场调研分析报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对中国的运动鞋服产业进行了全面分析,并且对产业链上中下游,特别是中游加工环节和下游用户行为进行了深度调研,并提出了趋势预判。
On May 7, 2021, iiMedia Research, a world-renowned third-party data mining and analysis organization for the new economy industry, released the "2021 China Sports Footwear Industry Development Status and Market Research Analysis Report". Based on the basic data of iiMedia Data Center, iiMedia Consulting Business Intelligence Database, and iiMedia Business Opinion and Public Opinion Data Monitoring System, the report conducted a comprehensive analysis of China's sports shoes and apparel industry, and conducted a comprehensive analysis of the upper, middle and lower reaches of the industrial chain, especially the middle and downstream processing links. Downstream user behavior was investigated in depth, and trend predictions were put forward. -
艾媒咨询|2020Q2中国中药材行业季度数据监测报告
本报告研究涉及企业/品牌/案例:云南白药,天士力。
数据显示,2020年4-5月中药材价格指数小幅下降,行情总体较为震荡。艾媒咨询分析师认为,自第二季度起中药材基本不受新冠肺炎疫情影响,市场秩序趋于稳定,但需求仍然不足,中药材基本以减产居多,减产的信号给予商家部分信心,一旦消费情况好转,中药材价格会重新上涨,因此商家谨慎投资与积极备货双管齐下,导致第二季度中药材大盘指数震荡。
Data show that the price index of Chinese medicinal materials declined slightly from April to May 2020, and the market was generally volatile. iiMedia Research believe that since the second quarter, Chinese herbal medicines have basically not been affected by the new coronary pneumonia epidemic. The market order has stabilized, but demand is still insufficient. Basically, Chinese herbal medicines basically reduce production. The signal of reduced production gives businesses some confidence. Once consumed The situation improves, and the prices of Chinese herbal medicines will rise again. Therefore, merchants' cautious investment and active inventory preparation have taken two measures, leading to the second quarter Chinese herbal medicines market index shock. -
艾媒报告|2019-2021年中国中药材用户调研及延伸市场研究报告
本报告研究涉及企业/品牌/案例:同仁堂,片仔癀,东阿阿胶,太极集团,胡庆余堂,同仁牛黄清心丸,黄芪颗粒,雷氏丹参片,云峰气血口服液,太极五子衍宗丸,太极生力雄丸,仲景左归丸,一笑堂龟甲壳,白云山复方丹参片,天士力养血清脑颗粒,白云山夏桑菊颗粒,白云山板蓝根颗粒
随着居民消费水平的提升和健康保健意识的增强,总体健康需求在扩大,进而推动中医药市场的发展,2018年中国中药材市场规模达1246亿元,同比增长22.40%,预计到2024年,中药材市场规模将达2004亿元。
iiMedia Research(艾媒咨询)调查显示,2019年接近五成受访者购买过中药材,滋补养生和治病是购买中药材的两大目的。由于中医药应用范围广泛,中医药产业链不断扩展延伸,并加速扩展和整合。同仁堂、片仔癀、东阿阿胶等中药巨头企业纷纷布局中药材后市场,建设中药大健康产业,如植物提取物、保健食品、中药化妆品等,已成为我国生命健康产业中最具成长性的组成部分。
According to the iiMedia Research survey, nearly 50% of respondents have bought Chinese herbal medicines in 2019, and tonic sage and cure are the two main purposes for buying Chinese herbal medicines. Due to the wide range of applications of Chinese medicine, the Chinese medicine industry chain continues to expand and expand and accelerate the expansion and integration. Tongrentang, tablets, Dong'a gum and other Chinese medicine giant enterprises have laid out the chinese medicine after the market, the construction of chinese medicine large health industry, such as plant extracts, health food, Chinese medicine cosmetics, etc., has become China's life and health industry in the most growth component.
(以下为节选页,完整版共88页) -
艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告
本报告研究涉及企业/品牌/案例:白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业,培力控股,盛实百草,芍花堂,亳药千草,汇群中药
国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research(艾媒咨询)调查显示,有49%的受访用户倾向中医药治疗,与西药基本持平。2018年中国中药材市场规模达1246亿元,同比增长22.40%,在巨大的需求驱动下,中药材种植面积扩大,药材产量将会持续增长。
中药材主要包括上游种植、养殖市场,中游流通市场和下游销售市场三大环节。目前,中药饮片和中成药生产是中药产业的核心,主要包括中药加工,包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面,行业销售收入增速分别在2016和2018年触底回升,华润三九、中国中药、红日药业等上市公司表现良好;中药配方颗粒方面,2006-2016年,中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%,中药配方颗粒或将成为中药饮片加工行业应用广泛的产品;中成药方面,随着国家医改政策的推行,中成药消费需求趋于合理,中成药产量开始回落,但仍处于一个比较高的产量水平,云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。
Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well.
- 1
- 2
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告